Skip to main content

Enablex Side Effects

Generic name: darifenacin

Medically reviewed by Last updated on Sep 23, 2023.

Note: This document contains side effect information about darifenacin. Some dosage forms listed on this page may not apply to the brand name Enablex.

Applies to darifenacin: oral tablet extended release.

Serious side effects of Enablex

Along with its needed effects, darifenacin (the active ingredient contained in Enablex) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking darifenacin:

Less common

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking darifenacin:

Symptoms of overdose

Other side effects of Enablex

Some side effects of darifenacin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to darifenacin: oral tablet extended release.


Postmarketing reports: Palpitations, syncope[Ref]


Very common (10% or more): Dry mouth (up to 35%), constipation (up to 21%)

Common (1% to 10%): Abdominal pain, nausea, dyspepsia, diarrhea

Uncommon (0.1% to 1%): Vomiting, flatulence, mouth ulceration, hyperhidrosis

Frequency not reported: Angioedema[Ref]


Common (1% to 10%): Dry skin, pruritus, rash

Postmarketing reports: Erythema multiforme, interstitial granuloma annulare[Ref]


Common (1% to 10%): Nasal dryness, bronchitis, respiratory tract infection, pharyngitis

Uncommon (0.1% to 1%): Dyspnea, cough, rhinitis[Ref]


Most adverse events were mild or moderate and mostly occurred during the first 2 weeks of treatment.[Ref]


Uncommon (0.1% to 1%): Urinary tract infection, urinary retention, urinary tract disorder, bladder pain, erectile dysfunction, vaginitis[Ref]


Uncommon (0.1% to 1%): Weight gain[Ref]


Uncommon (0.1% to 1%): Aspartate aminotransferase increased, alanine aminotransferase increased[Ref]


Postmarketing reports: Generalized hypersensitivity reactions including angioedema[Ref]


Common (1% to 10%): Influenza syndrome[Ref]


Common (1% to 10%): Back pain

Uncommon (0.1% to 1%): Arthralgia[Ref]

Nervous system

Very common (10% or more): Headache

Uncommon (0.1% to 1%): Dizziness, dysgeusia, somnolence[Ref]


Common (1% to 10%): Dry eye

Uncommon (0.1% to 1%): Visual disturbance, blurred vision[Ref]


Uncommon (0.1% to 1%): Edema, peripheral edema, face edema, asthenia, aspartate aminotransferase increased, alanine aminotransferase increased, accidental injury, pain[Ref]


Uncommon (0.1% to 1%): Insomnia, abnormal thinking

Postmarketing reports: Depressed mood, altered mood, hallucination[Ref]


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Darifenacin ER (darifenacin). Cipla USA Inc. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.